Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference newsletter


  Ovarian Neoplasms

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 69 articles:
HTML format



Single Articles


    September 2020
  1. LIU L, Yuan L, Huang D, Han Q, et al
    miR126 regulates the progression of epithelial ovarian cancer in vitro and in vivo by targeting VEGFA.
    Int J Oncol. 2020;57:825-834.
    PubMed     Abstract available


    January 2020
  2. BU H, Li Y, Jin C, Yu H, et al
    Overexpression of PRC1 indicates a poor prognosis in ovarian cancer.
    Int J Oncol. 2020 Jan 10. doi: 10.3892/ijo.2020.4959.
    PubMed     Abstract available


  3. FENG Y, Tang Y, Mao Y, Liu Y, et al
    PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming.
    Int J Oncol. 2020 Jan 10. doi: 10.3892/ijo.2020.4958.
    PubMed     Abstract available


    December 2019
  4. LEE SY, Kwon J, Woo JH, Kim KH, et al
    Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells.
    Int J Oncol. 2019 Dec 23. doi: 10.3892/ijo.2019.4949.
    PubMed     Abstract available


    November 2019
  5. LIU Q, Liu H, Li L, Dong X, et al
    ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
    Int J Oncol. 2019 Nov 14. doi: 10.3892/ijo.2019.4913.
    PubMed     Abstract available


  6. BAI Y, Li LD, Li J, Chen RF, et al
    A FXYD5/TGFbeta/SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
    Int J Oncol. 2019 Nov 13. doi: 10.3892/ijo.2019.4911.
    PubMed     Abstract available


    September 2019
  7. YE W, Ni Z, Yicheng S, Pan H, et al
    Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNAMeg3/miR421/PDGFRA axis.
    Int J Oncol. 2019 Sep 30. doi: 10.3892/ijo.2019.4887.
    PubMed     Abstract available


  8. LI R, Wang Y, Xu Y, He X, et al
    Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
    Int J Oncol. 2019 Sep 10. doi: 10.3892/ijo.2019.4875.
    PubMed     Abstract available


    July 2019
  9. SEKIYA A, Suzuki S, Tanaka A, Hattori S, et al
    Interleukin33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.
    Int J Oncol. 2019 Jul 17. doi: 10.3892/ijo.2019.4845.
    PubMed     Abstract available


    June 2019
  10. JIANG S, Chang H, Deng S, Fan D, et al
    Icariin enhances the chemosensitivity of cisplatinresistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Int J Oncol. 2019;54:1933-1942.
    PubMed     Abstract available


    May 2019
  11. WANG L, Chen T, Li X, Yan W, et al
    USP39 promotes ovarian cancer malignant phenotypes and carboplatin chemoresistance.
    Int J Oncol. 2019 May 29. doi: 10.3892/ijo.2019.4818.
    PubMed     Abstract available


  12. GUAN W, Wang X, Lin Q, Zhang J, et al
    Transforming growth factorbeta/miR1433p/cystatin B axis is a therapeutic target in human ovarian cancer.
    Int J Oncol. 2019 May 28. doi: 10.3892/ijo.2019.4815.
    PubMed     Abstract available


  13. KIM BI, Kim JH, Sim DY, Nam M, et al
    Inhibition of JAK2/STAT3 and activation of caspase9/3 are involved in KYS05090Sinduced apoptosis in ovarian cancer cells.
    Int J Oncol. 2019 May 3. doi: 10.3892/ijo.2019.4795.
    PubMed     Abstract available


  14. BU S, Li B, Wang Q, Gu T, et al
    Epithelial ovarian cancer stemlike cells are resistant to the cellular lysis of cytokineinduced killer cells via HIF1Amediated downregulation of ICAM1.
    Int J Oncol. 2019 May 3. doi: 10.3892/ijo.2019.4794.
    PubMed     Abstract available


    March 2019
  15. ZHANG W, Ou X, Wu X
    Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis.
    Int J Oncol. 2019 Mar 7. doi: 10.3892/ijo.2019.4742.
    PubMed     Abstract available


    February 2019
  16. LEE J, An S, Jung JH, Kim K, et al
    MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.
    Int J Oncol. 2019 Feb 27. doi: 10.3892/ijo.2019.4730.
    PubMed     Abstract available


  17. CHEN YN, Ren CC, Yang L, Nai MM, et al
    MicroRNA let7d5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.
    Int J Oncol. 2019 Feb 27. doi: 10.3892/ijo.2019.4731.
    PubMed     Abstract available


    December 2018
  18. TAE IH, Park EY, Dey P, Son JY, et al
    Novel SIRT1 inhibitor 15-deoxy-Delta12,14-prostaglandin J2 and its derivatives exhibit anticancer activity through apoptotic or autophagic cell death pathways in SKOV3 cells.
    Int J Oncol. 2018;53:2518-2530.
    PubMed     Abstract available


    November 2018
  19. LI S, Zhao X, Chang S, Li Y, et al
    ERp57small interfering RNA silencing can enhance the sensitivity of drugresistant human ovarian cancer cells to paclitaxel.
    Int J Oncol. 2018 Nov 7. doi: 10.3892/ijo.2018.4628.
    PubMed     Abstract available


  20. CHEN J, Jia Y, Jia ZH, Zhu Y, et al
    Silencing the expression of MTDH increases the radiation sensitivity of SKOV3 ovarian cancer cells and reduces their proliferation and metastasis.
    Int J Oncol. 2018;53:2180-2190.
    PubMed     Abstract available


    September 2018
  21. NING L, Long B, Zhang W, Yu M, et al
    Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer.
    Int J Oncol. 2018 Sep 20. doi: 10.3892/ijo.2018.4566.
    PubMed     Abstract available


    July 2018
  22. SKIRNISDOTTIR I, Akerud H, Seidal T
    Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGFR2 in patients with ovarian cancer at FIGO stages I-II.
    Int J Oncol. 2018 Jul 31. doi: 10.3892/ijo.2018.4511.
    PubMed     Abstract available


  23. YOSHIDA M, Taguchi A, Kawana K, Ogishima J, et al
    Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity.
    Int J Oncol. 2018 Jul 26. doi: 10.3892/ijo.2018.4504.
    PubMed     Abstract available


  24. LIU J, Zheng M, Qi Y, Wang H, et al
    Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer.
    Int J Oncol. 2018 Jul 20. doi: 10.3892/ijo.2018.4496.
    PubMed     Abstract available


  25. XU Y, Gao W, Zhang Y, Wu S, et al
    ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
    Int J Oncol. 2018 Jul 9. doi: 10.3892/ijo.2018.4476.
    PubMed     Abstract available


    June 2018
  26. LIU J, Liu D, Liu JJ, Zhao C, et al
    Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells.
    Int J Oncol. 2018 Jun 12. doi: 10.3892/ijo.2018.4437.
    PubMed     Abstract available


    May 2018
  27. SONG J, Zhang W, Wang S, Liu K, et al
    A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
    Int J Oncol. 2018 May 11. doi: 10.3892/ijo.2018.4403.
    PubMed     Abstract available


  28. SHEN L, Sun B, Sheng J, Yu S, et al
    PGC1alpha promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis.
    Int J Oncol. 2018 May 9. doi: 10.3892/ijo.2018.4401.
    PubMed     Abstract available


    April 2018
  29. QIU C, Wang Y, Wang X, Zhang Q, et al
    Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Int J Oncol. 2018 Apr 4. doi: 10.3892/ijo.2018.4360.
    PubMed     Abstract available


  30. WANG Y, Qiu C, Lu N, Liu Z, et al
    FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Int J Oncol. 2018 Apr 4. doi: 10.3892/ijo.2018.4359.
    PubMed     Abstract available


    March 2018
  31. TANG G, Guo J, Zhu Y, Huang Z, et al
    Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4343.
    PubMed     Abstract available


    January 2018
  32. XU M, Xiao J, Chen M, Yuan L, et al
    miR1495p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway.
    Int J Oncol. 2018 Jan 24. doi: 10.3892/ijo.2018.4252.
    PubMed     Abstract available


    November 2017
  33. CHANG RK, Li X, Mu N, Hrydziuszko O, et al
    MicroRNA expression profiles in nonepithelial ovarian tumors.
    Int J Oncol. 2017 Nov 10. doi: 10.3892/ijo.2017.4200.
    PubMed     Abstract available


    October 2017
  34. PENG F, Zhong Y, Liu Y, Zhang Y, et al
    SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.
    Int J Oncol. 2017 Oct 19. doi: 10.3892/ijo.2017.4168.
    PubMed     Abstract available


  35. OZRETIC P, Trnski D, Musani V, Maurac I, et al
    Non-canonical Hedgehog signaling activation in ovarian borderline tumors and ovarian carcinomas.
    Int J Oncol. 2017 Oct 12. doi: 10.3892/ijo.2017.4156.
    PubMed     Abstract available


  36. SHETA R, Bachvarova M, Plante M, Gregoire J, et al
    Altered expression of different GalNActransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
    Int J Oncol. 2017 Oct 9. doi: 10.3892/ijo.2017.4147.
    PubMed     Abstract available


  37. PAN H, Wang F, Rankin GO, Rojanasakul Y, et al
    Inhibitory effect of black tea pigments, theaflavin3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.
    Int J Oncol. 2017 Oct 3. doi: 10.3892/ijo.2017.4145.
    PubMed     Abstract available


  38. GUO J, Cai J, Zhang Y, Zhu Y, et al
    Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study.
    Int J Oncol. 2017;51:1199-1208.
    PubMed     Abstract available


    September 2017
  39. BU S, Zhang Q, Wang Q, Lai D, et al
    Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGFbeta1-mediated cell cycle arrest.
    Int J Oncol. 2017 Sep 14. doi: 10.3892/ijo.2017.4123.
    PubMed     Abstract available


    August 2017
  40. QIU JJ, Zhang XD, Tang XY, Zheng TT, et al
    ElncRNA1, a long non-coding RNA that is transcriptionally induced by oestrogen, promotes epithelial ovarian cancer cell proliferation.
    Int J Oncol. 2017;51:507-514.
    PubMed     Abstract available


    May 2017
  41. LI X, Jin Y, Mu Z, Chen W, et al
    MicroRNA146a5p enhances cisplatininduced apoptosis in ovarian cancer cells by targeting multiple antiapoptotic genes.
    Int J Oncol. 2017 May 29. doi: 10.3892/ijo.2017.4023.
    PubMed     Abstract available


  42. PALMA FLORES C, Garcia-Vazquez R, Gallardo Rincon D, Ruiz-Garcia E, et al
    MicroRNAs driving invasion and metastasis in ovarian cancer: Opportunities for translational medicine (Review).
    Int J Oncol. 2017;50:1461-1476.
    PubMed     Abstract available


  43. YANG J, Wang Y, Zeng Z, Qiao L, et al
    Smad4 deletion in blood vessel endothelial cells promotes ovarian cancer metastasis.
    Int J Oncol. 2017;50:1693-1700.
    PubMed     Abstract available


    April 2017
  44. XU J, Jiang N, Shi H, Zhao S, et al
    [Corrigendum] miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.
    Int J Oncol. 2017 Apr 27. doi: 10.3892/ijo.2017.3977.
    PubMed     Abstract available


    March 2017
  45. DEVOR EJ, Gonzalez-Bosquet J, Warrier A, Reyes HD, et al
    p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.
    Int J Oncol. 2017 Mar 23. doi: 10.3892/ijo.2017.3931.
    PubMed     Abstract available


  46. XU J, Jiang N, Shi H, Zhao S, et al
    miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.
    Int J Oncol. 2017 Mar 16. doi: 10.3892/ijo.2017.3915.
    PubMed     Abstract available


  47. YOKOYAMA T, Kohn EC, Brill E, Lee JM, et al
    Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.
    Int J Oncol. 2017 Mar 15. doi: 10.3892/ijo.2017.3914.
    PubMed     Abstract available


  48. CHA HJ, Choi JH, Park IC, Kim CH, et al
    Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells.
    Int J Oncol. 2017 Mar 15. doi: 10.3892/ijo.2017.3913.
    PubMed     Abstract available


  49. LI J, Li Q, Huang H, Li Y, et al
    Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer.
    Int J Oncol. 2017 Mar 7. doi: 10.3892/ijo.2017.3898.
    PubMed     Abstract available


  50. WANG Y, Compton C, Rankin GO, Cutler SJ, et al
    3-Hydroxyterphenyllin, a natural fungal metabolite, induces apoptosis and S phase arrest in human ovarian carcinoma cells.
    Int J Oncol. 2017 Mar 2. doi: 10.3892/ijo.2017.3894.
    PubMed     Abstract available


    February 2017
  51. VERA CA, Orostica L, Gabler F, Ferreira A, et al
    The nerve growth factor alters calreticulin translocation from the endoplasmic reticulum to the cell surface and its signaling pathway in epithelial ovarian cancer cells.
    Int J Oncol. 2017 Feb 28. doi: 10.3892/ijo.2017.3892.
    PubMed     Abstract available


  52. SATO M, Kawana K, Adachi K, Fujimoto A, et al
    Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
    Int J Oncol. 2017 Feb 23. doi: 10.3892/ijo.2017.3891.
    PubMed     Abstract available


  53. PARK SH, Chung YJ, Song JY, Kim SI, et al
    Mullerian inhibiting substance inhibits an ovarian cancer cell line via beta-catenin interacting protein deregulation of the Wnt signal pathway.
    Int J Oncol. 2017 Feb 13. doi: 10.3892/ijo.2017.3874.
    PubMed     Abstract available


  54. ZHU X, Ji M, Han Y, Guo Y, et al
    PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment.
    Int J Oncol. 2017 Feb 10. doi: 10.3892/ijo.2017.3873.
    PubMed     Abstract available


    January 2017
  55. ZHOU G, Peng F, Zhong Y, Chen Y, et al
    Rhein suppresses matrix metalloproteinase production by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells.
    Int J Oncol. 2017 Jan 17. doi: 10.3892/ijo.2017.3853.
    PubMed     Abstract available


    December 2016
  56. OTTE A, Yang Y, von der Ohe J, Melzer C, et al
    SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment.
    Int J Oncol. 2016;49:2453-2463.
    PubMed     Abstract available


    November 2016
  57. FU QR, Song W, Deng YT, Li HL, et al
    ESC-3 induces apoptosis of human ovarian carcinomas through Wnt/beta-catenin and Notch signaling in vitro and in vivo.
    Int J Oncol. 2016 Nov 18. doi: 10.3892/ijo.2016.3773.
    PubMed     Abstract available


  58. TURCONI G, Scaldaferri D, Fabbri M, Monti L, et al
    RNASET2 silencing affects miRNAs and target gene expression pattern in a human ovarian cancer cell model.
    Int J Oncol. 2016 Nov 9. doi: 10.3892/ijo.2016.3763.
    PubMed     Abstract available


    October 2016
  59. XIE Q, Su J, Jiao B, Shen L, et al
    ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
    Int J Oncol. 2016 Oct 13. doi: 10.3892/ijo.2016.3733.
    PubMed     Abstract available


    September 2016
  60. CHEN WC, Hsu HP, Li CY, Yang YJ, et al
    Cancer stem cell marker CD90 inhibits ovarian cancer formation via beta3 integrin.
    Int J Oncol. 2016 Sep 15. doi: 10.3892/ijo.2016.3691.
    PubMed     Abstract available


    June 2016
  61. WANG D, Saga Y, Sato N, Nakamura T, et al
    The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.
    Int J Oncol. 2016;48:2303-9.
    PubMed     Abstract available


    May 2016
  62. ROGERS-BROADWAY KR, Chudasama D, Pados G, Tsolakidis D, et al
    Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.
    Int J Oncol. 2016 May 18. doi: 10.3892/ijo.2016.3531.
    PubMed     Abstract available


    March 2016
  63. AGUILAR-ROJAS A, Perez-Solis MA, Maya-Nunez G
    The gonadotropin-releasing hormone system: Perspectives from reproduction to cancer (Review).
    Int J Oncol. 2016;48:861-8.
    PubMed     Abstract available


  64. MANKARIOUS A, Dave F, Pados G, Tsolakidis D, et al
    The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro.
    Int J Oncol. 2016 Mar 1. doi: 10.3892/ijo.2016.3410.
    PubMed     Abstract available


    February 2016
  65. ANTONILLI M, Rahimi H, Visconti V, Napoletano C, et al
    Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
    Int J Oncol. 2016 Feb 8. doi: 10.3892/ijo.2016.3386.
    PubMed     Abstract available


    January 2016
  66. LI L, Yu J, Duan Z, Dang HX, et al
    The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma.
    Int J Oncol. 2016 Jan 25. doi: 10.3892/ijo.2016.3355.
    PubMed     Abstract available


  67. SKIRNISDOTTIR I, Seidal T, Akerud H
    The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II.
    Int J Oncol. 2016 Jan 12. doi: 10.3892/ijo.2016.3333.
    PubMed     Abstract available


    November 2015
  68. NAKAYAMA K, Rahman MT, Rahman M, Nakamura K, et al
    CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Int J Oncol. 2015 Nov 26. doi: 10.3892/ijo.2015.3268.
    PubMed     Abstract available


  69. GAO Y, Rankin GO, Tu Y, Chen YC, et al
    Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways.
    Int J Oncol. 2015 Nov 20. doi: 10.3892/ijo.2015.3257.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: